DIS-CHEM PHARMACIES LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.28 ZAR | -0.31% |
|
+1.00% | +5.18% |
| May. 31 | Dis-Chem Pharmacies Limited Reports Earnings Results for the Full Year Ended February 29, 2024 | CI |
| May. 31 | Transcript : Dis-Chem Pharmacies Limited, 2024 Earnings Call, May 31, 2024 |
Valuation
| Fiscal Period: February | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,595 | 19,254 | 29,767 | 23,265 | 26,242 | 27,675 | - | - |
| Enterprise Value (EV) 1 | 21,842 | 23,190 | 33,569 | 27,952 | 26,242 | 30,576 | 29,397 | 28,004 |
| P/E ratio | 31.1 x | 28.8 x | 34.9 x | 23.3 x | 26.6 x | 24 x | 19.6 x | 17 x |
| Yield | 0.59% | 1.39% | 1.15% | 1.72% | - | 1.76% | 2.13% | 2.66% |
| Capitalization / Revenue | 0.78 x | 0.73 x | 0.98 x | 0.71 x | 0.72 x | 0.69 x | 0.62 x | 0.55 x |
| EV / Revenue | 0.91 x | 0.88 x | 1.1 x | 0.86 x | 0.72 x | 0.76 x | 0.66 x | 0.56 x |
| EV / EBITDA | 12 x | 11.8 x | 14 x | 10.2 x | 9.09 x | 9.53 x | 7.98 x | 6.75 x |
| EV / FCF | 24.4 x | 32.1 x | - | -118 x | - | 20.6 x | 17.6 x | 12.5 x |
| FCF Yield | 4.09% | 3.12% | - | -0.84% | - | 4.86% | 5.67% | 8.03% |
| Price to Book | 8.04 x | 6.53 x | 8.8 x | 5.92 x | - | 5.37 x | 4.6 x | 4.09 x |
| Nbr of stocks (in thousands) | 860,084 | 859,553 | 859,829 | 860,084 | 859,269 | 857,350 | - | - |
| Reference price 2 | 21.62 | 22.40 | 34.62 | 27.05 | 30.54 | 32.28 | 32.28 | 32.28 |
| Announcement Date | 5/20/20 | 5/21/21 | 5/23/22 | 5/18/23 | 5/31/24 | - | - | - |
1ZAR in Million2ZAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: February | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23,984 | 26,278 | 30,407 | 32,664 | 36,283 | 40,162 | 44,780 | 50,335 |
| EBITDA 1 | 1,824 | 1,971 | 2,394 | 2,746 | 2,886 | 3,207 | 3,684 | 4,146 |
| EBIT 1 | 1,248 | 1,266 | 1,539 | 1,744 | 1,779 | 2,045 | 2,396 | 2,706 |
| Operating Margin | 5.21% | 4.82% | 5.06% | 5.34% | 4.9% | 5.09% | 5.35% | 5.38% |
| Earnings before Tax (EBT) 1 | 868.8 | 940.9 | 1,227 | 1,417 | 1,385 | 1,592 | 1,971 | 2,222 |
| Net income 1 | 598.2 | 668.7 | 853.4 | 1,000 | 984.5 | 1,116 | 1,389 | 1,578 |
| Net margin | 2.49% | 2.54% | 2.81% | 3.06% | 2.71% | 2.78% | 3.1% | 3.14% |
| EPS 2 | 0.6960 | 0.7780 | 0.9920 | 1.163 | 1.147 | 1.346 | 1.643 | 1.904 |
| Free Cash Flow 1 | 893.6 | 722.9 | - | -236 | - | 1,485 | 1,666 | 2,248 |
| FCF margin | 3.73% | 2.75% | - | -0.72% | - | 3.7% | 3.72% | 4.47% |
| FCF Conversion (EBITDA) | 48.99% | 36.68% | - | - | - | 46.32% | 45.22% | 54.23% |
| FCF Conversion (Net income) | 149.38% | 108.1% | - | - | - | 133.11% | 119.91% | 142.46% |
| Dividend per Share 2 | 0.1280 | 0.3110 | 0.3970 | 0.4660 | - | 0.5671 | 0.6871 | 0.8578 |
| Announcement Date | 5/20/20 | 5/21/21 | 5/23/22 | 5/18/23 | 5/31/24 | - | - | - |
1ZAR in Million2ZAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: February | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2023 S1 |
|---|---|---|---|---|---|
| Net sales | 12,137 | 12,807 | 13,471 | 14,936 | - |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income 1 | - | - | - | - | 602.5 |
| Net margin | - | - | - | - | - |
| EPS 2 | 0.3860 | 0.3600 | 0.4180 | 0.4840 | 0.7000 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 5/20/20 | 11/5/20 | 5/21/21 | 11/3/21 | 9/30/22 |
1ZAR in Million2ZAR
Estimates
Balance Sheet Analysis
| Fiscal Period: February | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 3,247 | 3,936 | 3,802 | 4,687 | - | 2,901 | 1,722 | 329 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.78 x | 1.997 x | 1.588 x | 1.707 x | - | 0.9045 x | 0.4674 x | 0.0793 x |
| Free Cash Flow 1 | 894 | 723 | - | -236 | - | 1,485 | 1,666 | 2,248 |
| ROE (net income / shareholders' equity) | 28.9% | 25.9% | 27.4% | 27.7% | - | 23.6% | 24.8% | 25.3% |
| ROA (Net income/ Total Assets) | 5.67% | 5.63% | - | 6.76% | - | 6.7% | 7.5% | 7.8% |
| Assets 1 | 10,554 | 11,885 | - | 14,796 | - | 16,655 | 18,512 | 20,234 |
| Book Value Per Share 2 | 2.690 | 3.430 | 3.940 | 4.570 | - | 6.010 | 7.020 | 7.890 |
| Cash Flow per Share 2 | - | - | 1.600 | 0.9900 | - | 1.690 | 2.670 | 3.100 |
| Capex 1 | 363 | 401 | 377 | 1,090 | - | 673 | 854 | 772 |
| Capex / Sales | 1.51% | 1.53% | 1.24% | 3.34% | - | 1.68% | 1.91% | 1.53% |
| Announcement Date | 5/20/20 | 5/21/21 | 5/23/22 | 5/18/23 | 5/31/24 | - | - | - |
1ZAR in Million2ZAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
32.28
ZAR
Average target price
33.18
ZAR
Spread / Average Target
+2.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.18% | 1.5B | |
| -37.08% | 10.04B | |
| -17.45% | 7.21B | |
| -15.46% | 5.59B | |
| -12.49% | 4.88B | |
| -3.21% | 4.57B | |
| +68.00% | 4.4B | |
| -4.97% | 4B | |
| -30.40% | 2.72B | |
| -18.69% | 2.63B |
- Stock Market
- Equities
- DCP Stock
- Financials Dis-Chem Pharmacies Limited
